CytomX Therapeutics is a biotechnology company focused on revolutionizing the monoclonal antibody field by creating a new generation of highly targeted antibody therapeutics. CytomX's novel Probody™ Platform offers a highly differentiated approach to developing antibody therapeutics, and is based on a robust and growing intellectual property estate. This novel platform is driving the development of Probodies, which are masked antibodies that remain inert in healthy tissue but are activated by proteases within the disease microenvironment. This new level of tissue activation and selectivity enables CytomX to access new targets and expand the therapeutic index of existing targets.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/31/12 | $41,000,000 | Series B |
Canaan Partners Roche Venture Fund | undisclosed |
